Kliniken der Stadt Koln, a network of urban hospitals in Germany, has started using Luminex's xTAG Gastrointestinal Pathogen Panel (GPP) as a first-line screen for patients who are suspected of having an E coli infection.

Luminex’s xTAG GPP detects hemolytic-uremic syndrome (HUS) causing Shiga-like toxin producing E. coli strain (STEC).

GPP can also detect 15 of the most common disease-causing gastrointestinal pathogens, including viruses, bacteria and parasites, such as E. coli, Campylobacter, Salmonella and C. difficile all within 5 hours.

The company’s xMAP multiplex solutions include a technology platform that delivers bioassay results to markets as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including genomic and proteomic research markets.

Frauke Mattner of Kliniken der Stadt Institute of Pathology and Institute for Hygiene said the ability of xTAG GPP to detect not only several different types of E. coli, but also the presence of the Stx-2 gene, a marker of this more severe STEC strain, is allowing rapid identification of patients who are suffering from an infection of this strain.

The xTAG GPP received CE mark approval in May of 2011 from European regulatory authorities.